

Cost-savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates

Marion Afonso¹, Daisy Ng-Mak², Yuqian Shen³, Shariq Ali², Amy Chen², Ahmed Mekky⁴, Wedad Alnemari⁵, Ion Agirrezabal⁶

¹Sanofi, Gentilly, France; ²Sanofi, Cambridge, MA, USA; ³Sanofi, Bridgewater, NJ, USA; ⁴Sanofi, Dubai, UAE; ⁵Sanofi, Riyadh, KSA; ⁶Sanofi, Barcelona, Spain

Poster No. EE293



Copies of this poster obtained through Quick Response (QR) Code are for personal use only

OBJECTIVE



To evaluate cost-savings resulting from the reduction in clotting factor concentrates (CFC)/bypassing agents (BPAs) usage for managing breakthrough bleeds with fitusiran prophylaxis in the United Arab Emirates (UAE).

BACKGROUND

- Fitusiran is a subcutaneous antithrombin (AT)-lowering therapeutic, that increases thrombin generation to restore haemostasis in people with haemophilia (PwH).¹
- In March 2025, the United States Food and Drug Administration (FDA) approved fitusiran for preventing and reducing bleeds in people with haemophilia A or B (PwHA or PwHB) aged ≥12 years, with or without inhibitors.¹ Subsequently, it was approved in UAE in April 2025.²
- In the ATLAS-OLE (NCT03754790) trial, antithrombin-based dosing regimen (AT-DR; targeting AT levels of 15%–35%) of fitusiran was associated with a meaningful reduction in CFCs/BPAs utilisation for managing breakthrough bleeding episodes versus CFC/BPA prophylaxis.³

METHODS

A cost analysis model was developed in Microsoft Excel.


- CFC/BPA episodic treatments used during breakthrough bleeds considered**
 - For PwHA without inhibitors: octocog alfa, efmoroctocog alfa, and ruriococog alfa pegol
 - For PwHB without inhibitors: nonacog alfa, albutrepenonacog alfa, and eftrenonacog alfa
 - For PwH with inhibitors: factor VIII inhibitor bypassing activity (FEIBA) and eptacog alfa
- Model inputs and assumptions**
 - Table 1** presents key inputs used for the calculation.
 - Average patient weight of 70.00 kg was used.⁴
 - Administration cost of 490 AED per infusion was used.⁵
 - The published drug prices in UAE were used as the drug costs in the analysis.⁶
 - The base-case assumed no vial sharing.
 - Percentage reduction in mean annualised weight-adjusted factor consumption with fitusiran AT-DR prophylaxis was based on the ATLAS-OLE data (**Figure 1**).³

Table 1. Cost-calculation model inputs.

On-demand treatment	Cost per pack (AED)	CFC/BPA dose per kg	CFC/BPA doses to resolve one bleed	Total CFC/BPA dose per bleed with CFC/BPA prophylaxis	Total CFC/BPA dose per bleed with fitusiran AT-DR prophylaxis
PwHA without inhibitors					
Octocog alfa	950.00	30	1.5	3,150.00	1,127.70
Efmoroctocog alfa	876.00	20	1.5	2,100.00	751.80
Ruriococog alfa pegol	1,409.50	30	1.5	3,150.00	1,127.70
PwHB without inhibitors					
Nonacog alfa	1,718.50	30	1.7	3,570.00	1,095.99
Albutrepenonacog alfa	2,971.00	30	1.7	3,570.00	1,095.99
Eftrenonacog alfa	1,391.50	30	1.7	3,570.00	1,095.99
PwH with inhibitors					
FEIBA	1,958.00	75	3.7	19,425.00	1,204.35
Eptacog alfa	3,703.00	90	6.0	37,800.00	13,494.60

AED, UAE Dirham; AT-DR, antithrombin-based dosing regimen; BPA, bypassing agent; CFC, clotting factor concentrate; IU, International Unit; PwH, people with haemophilia; PwHA, people with haemophilia A; PwHB, people with haemophilia B; UAE United Arab Emirates; USPI: United States prescribing information. Dose per kg for PwH on CFC/BPA prophylaxis were sourced from USPI⁷⁻¹⁴; Percentage reduction considered in factor consumption for PwH on fitusiran AT-DR prophylaxis are based on ATLAS-OLE data.³

Figure 1. Estimated reduction in the mean annualized weight-adjusted consumption of on-demand CFC/BPA for breakthrough bleeds management with fitusiran AT-DR prophylaxis compared with that with CFC/BPA prophylaxis.



■ Reduction in CFC/BPA consumption for breakthrough bleeds management with fitusiran AT-DR compared with CFC/BPA prophylaxis AT-DR, antithrombin-based dosing regimen; BPA, bypassing agent; CFC, clotting factor concentrate; FEIBA, factor VIII inhibitor bypassing activity; PwH, people with haemophilia; PwHA, people with haemophilia A; PwHB, people with haemophilia B.

Analysis

- The analysis calculated drug cost per bleed, administration cost per bleed, and combined total cost for each episodic treatment among PwH receiving CFC/BPA prophylaxis and among those on fitusiran AT-DR prophylaxis.
- The difference between the costs of CFC/BPA prophylaxis and fitusiran AT-DR prophylaxis was presented as potential cost-savings with fitusiran AT-DR prophylaxis.
- A scenario analysis was conducted to evaluate the impact of vial sharing.

CONCLUSIONS




- In the UAE, fitusiran AT-DR prophylaxis may considerably reduce the costs associated with episodic treatments for breakthrough bleeds among PwH compared with that by CFC/BPA prophylaxis.
- PwH with inhibitors may experience larger cost-savings (AED 71,846 [\$ 19,398] to AED 90,761 [\$ 24,505]) than those without inhibitors.
- For payers and healthcare systems, these savings may substantially reduce annual budgets for haemophilia bleed management.

RESULTS

PwH without inhibitors

- Fitusiran AT-DR prophylaxis resulted in cost-saving per bleed ranging from AED 4,625 (\$ 1,249) to AED 11,521 (\$ 3,111) among PwHA without inhibitors (**Figure 2**).


Figure 2. Treatment cost of managing breakthrough bleeds with CFC prophylaxis and fitusiran AT-DR prophylaxis among PwHA without inhibitors.



AED, UAE Dirham; AT-DR, antithrombin-based dosing regimen; CFC, clotting factor concentrate; PwHA, people with haemophilia A.

- Fitusiran AT-DR prophylaxis led to cost-saving per bleed between AED 8,935 (\$ 2,412) and AED 30,053 (\$ 8,114) among PwHB without inhibitors (**Figure 3**).

Figure 3. Treatment cost of breakthrough bleeds management with CFC prophylaxis and fitusiran AT-DR prophylaxis among PwHB without inhibitors.




AED, UAE Dirham; AT-DR, antithrombin-based dosing regimen; CFC, clotting factor concentrate; PwHB, people with haemophilia B.

PwH with inhibitors

- Fitusiran AT-DR prophylaxis demonstrated savings per bleed ranging from AED 71,846 (\$ 19,398) to AED 90,761 (\$ 24,505) in PwH with inhibitors (**Figure 4**).

Figure 4. Treatment cost of managing breakthrough bleeds with BPA prophylaxis and fitusiran AT-DR prophylaxis among PwH with inhibitors.



AED, UAE Dirham; AT-DR, antithrombin-based dosing regimen; BPA, bypassing agent; FEIBA, factor VIII inhibitor bypassing activity; PwH, people with haemophilia.

Scenario analysis considering vial sharing

- The cost-saving associated with fitusiran AT-DR prophylaxis remained substantial across all haemophilia types and treatments.
 - Among PwH without inhibitors, cost-saving per bleed ranged from AED 4,969 (\$ 1,342) to AED 11,647 (\$ 3,145) in PwHA, and from AED 8,846 (\$ 2,388) to AED 29,744 (\$ 8,031) in PwHB.
 - In PwH with inhibitors, cost-saving per bleed ranged from AED 72,711 (\$ 19,632) to 91,892 (\$ 24,811).

REFERENCES

- QFTLIA® (fitusiran) Subcutaneous Injection Prescribing Information. Sanofi. 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219019s000bl.pdf. Accessed 30 May 2025.
- Registered medical product directory. United Arab Emirates Ministry of Health & Prevention. Available at: <https://mohap.gov.ae/en/registered-medical-product-directory/?keyword=Fitusiran>. Accessed 15 October 2025.
- Pipe SW, Kavakli K, Matsushita T, et al. *Blood*. 2024;144(Supplement 1):128-128.
- Anan I, Taha S, Sedrak AS, et al. *Value in Health*. 2022;25(12):S94.
- Your Health, Our Priority - Experience the Benefits of IV Drip Therapy in Riyadh. Available at: <https://www.enfieldroyalsaudia.com/ivdrip/#~:text=In%20Riyadh%2C%20Saudi%20Arabia%2C%20the,real%20cost%20may%20differ%20significantly.> Accessed 30 May 2025.
- Daman Drug Formulary. Available at: <https://www.damanhealth.ae/healthcare/pharmaceutical-benefits/daman-drug-formulary/>. Accessed 30 May 2025.
- ELOCTATE® Prescribing Information. Available at: <https://www.fda.gov/media/88746/download?attachment>. Accessed 30 May 2025.
- ADYNOVATE® Prescribing Information. Available at: https://www.shirecontent.com/PI/PDFs/ADYNOVATE_USA_ENG.pdf. Accessed 30 May 2025.
- ADVATE® Prescribing Information. Available at: <https://www.shirecontent.com/PI/PDFs/ADVATEUSAENG.pdf>. Accessed 30 May 2025.
- ADVATE® Prescribing Information. Takeda Pharmaceuticals USA, Inc. Available at: <https://www.fda.gov/media/78852/download?attachment>. Accessed 30 May 2025.
- BeneFIX® Prescribing Information. Pfizer Inc. Available at: <https://www.google.com/url?sa=t&rl=1&url=https://www.fda.gov/media/78852/download?attachment&usq=AOvVaw3gGKlCKETZwYXh3PZYclfi&opi=89978449>. Accessed 30 May 2025.
- NovoSeven® Prescribing Information. Novo Nordisk Inc. Available at: <https://www.google.com/url?sa=t&rl=1&url=https://www.fda.gov/media/78852/download?attachment&usq=AOvVaw3gGKlCKETZwYXh3PZYclfi&opi=89978449>. Accessed 30 May 2025.
- IDELVION® Prescribing Information. CSL Behring LLC. Available at: <https://www.google.com/url?sa=t&rl=1&url=https://www.fda.gov/media/78852/download?attachment&usq=AOvVaw3gGKlCKETZwYXh3PZYclfi&opi=89978449>. Accessed 30 May 2025.
- ALPROLIX® Prescribing Information. Sanofi. Available at: <https://www.google.com/url?sa=t&rl=1&url=https://www.fda.gov/media/78852/download?attachment&usq=AOvVaw3gGKlCKETZwYXh3PZYclfi&opi=89978449>. Accessed 30 May 2025.

FUNDING

This study was funded by Sanofi.

CONFLICT OF INTERESTS

Marion Afonso, Daisy Ng-Mak, Yuqian Shen, Shariq Ali, Amy Chen, Ahmed Mekky, Wedad Alnemari and Ion Agirrezabal are employees of Sanofi and may hold stock and/or stock options in Sanofi.

ACKNOWLEDGMENT

Deepshikha Roy and Deepti Sharda from Sanofi provided medical writing and editorial assistance during the development of this poster, which was funded by Sanofi. Karuna Naik from Sanofi contributed to the planning, review, and coordination of this poster.